CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genetic Technologies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genetic Technologies Ltd
60-66 Hanover St, Fitzroy
Phone: +61 394151135p:+61 394151135 MELBOURNE, VIC  3065  Australia Ticker: GTGGTG

Business Summary
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Peter I.Rubinstein 5/18/2020 1/31/2018
Chief Executive Officer SimonMorriss 2/1/2021 2/1/2021
Chief Financial Officer, Company Secretary KathrynAndrews 3/25/2024 3/25/2024
5 additional Officers and Directors records available in full report.

Business Names
Business Name
AffinityDNA
EasyDNA
GENE
6 additional Business Names available in full report.

General Information
Number of Employees: 60 (As of 6/30/2023)
Outstanding Shares: 115,417,246 (As of 12/31/2023)
Shareholders: 4,846
Stock Exchange: ASX
Federal Tax Id: 000000000
Fax Number: +61 384127040


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024